





Natural History vs Real World Data

Klaus Mohnike
University Children's Hospital, Otto-von-Guericke University Magdeburg



Kathedrale, 1456



Univ. Kinderklinik, Bauhaus



F. Hundertwasser, 2010







Disclosures

Research funded by Novo-Nordisk, Pfizer, BioMarin, Lilly Receives honoraria for seminars by Roche, Novo-Nordisk, QED, BioMarin, Lilly



Achondroplasia: condition or disease?





Network
 Endocrine Conditions
 (Endo-ERN)









Natural History Data

AIM:

The Lifetime Impact of Achondroplasia Study in Europe (LIAISE; NCT03449368) to quantify the burden of achondroplasia among individuals across all ages

COHORT:

186 study patients mean age of 21.7 \pm 17.3 years (range 5.0–84.4)

METHOD:

- Demographic, clinical and healthcare resource use data from medical records
- Patient-reported outcomes questionnaires at the time of enrolment (quality of life [QoL], pain, functional independence, work productivity activity impairments)








Complications and healthcare resource use

In total, 94.6% of patients reported 66.6 events per 100 patient-year










Surgical Burden
72.0% of individuals had undergone at least one surgical procedure. event rate 21.5 per 100 person-years










Network **Endocrine Conditions** (Endo-ERN)

Quality of Life

Self-reported scores were typically higher than parent-reported scores










Quality of Life -adults

Negatively impacted domains: physical mobility, energy and pain









[ORPHA442]
The e-REC platform monthly new referrals of rare endocrine and bone conditions are reported

BONE DYSPLASIA

THYROID

Condition	Suspected Cases - Child (< 18)	Confirmed Cases - Child (< 18)
Osteogenesis Imperfecta [ORPHA666]	0	0
McCune-Albright syndrome [ORPHA562]	0	0
Achondroplasia [ORPHA15]	0	0



Network
 Endocrine Conditions
 (Endo-ERN)



7/2018 to 12/2022 reported new referrals with achondroplasia















■ PBD with disorganized development of skeletal components

■ Spondyloepiphyseal dysplasia congenita (SEDC)

Hypophosphatasia




■ PBD with micromelia (short limbs)

Achondroplasia

■ Multiple epiphyseal dysplasia and pseudoachondroplasia

<18y.	N of centers	28
	patients	462
>18y.	N of centers	22
	patients	481









Available natural history data will be evaluated by prospective standardized monitoring

- ✓ Co-morbidities including cervico-medullary compression, spinal stenosis, sleep apnea, bone deformities
- ✓ Current treatment for complications related to ACH is surgical intervention (foramen magnum decompression, spinal surgery, limb lengthening, etc.)
- Medical treatment until final adult height.








Network Endocrine Conditions (Endo-ERN)

Consensus on principles of management for achondroplasia (8 specialities & PAG from 7 countries)

Name	Speciality	Country
Alves, Inês	PAG	Portugal
Baujat, Genevieve	Genetics	France
Bedeschi, Maria Francesca	Genetics	Italy
Brizola, Evelisa	Genetics	Italy
Cheung, Moira	Ped. Endocrinologist	UK
Fredwall, Svein	Internal med	Norway
Hagenäs, Lars	Ped. Endocrinologist	Sweden
Innig, Florian	Patient Advocacy Group (PAG)	Germany
Kunkel, Philip	Neurosurgeon	Germany
Lampe, Christian	Neuropediatrician	Germany
Milrad, Josef	Neuropediatrician	Sweden
Mohnike, Klaus	Ped. Endocrinologist	Germany
Mordenti, Marina	Genetics	Italy
Mortier, Geert	Genetics	Belgium
Offiah, Amaka	Radiologist	UK
Palm, Katja	Ped. Endocrinologist	Germany
Quitman, Julia	Psychologist	Germany
Sessa, Marco	PAG	Italy










Real world evidence monitoring

Achondroplasia-specific modified version of CrescNet

Structured data collection

- · Enrolment after care givers consent
- · Standardized items:
 - Human Phenotype Ontology (HPO),
 - Logica Observation Identifiers Names and Codes (LOINC®)
- Documentation of clinical findings during visit, `real-time´
- · Self-reporting of questionnaires
 - Milestones
 - QoL (quality of life)



https://crescnet.org/ (University of Leipzig). This network has been developed by the Medical Faculty of the University of Leipzig and is dependent on financial donations and support in order to be able to fulfill its associated tasks.





Growth Network




Endocrine Conditions (Endo-ERN)



Orthopaedic findings (gibbus, etc.)

Measurement of the Intercondylar Distance, the Intermalleolar Distance and the Clinical Tibiofemoral Angle¹



Intercondylar Distance (ICD)

Measurement of the distance between the two medial femoral condyles with the inner ankles or medial foot edges just touching in neutral joint position.

Unit: cm (centimetre)

Tool: Measuring tape

Intermalleolar Distance (IMD)

Measurment of the distance between the two medial malleoli in neutral joint position.

Unit: cm (centimetre)

Tool: Measuring tape

clinical Tibiofemoral Angle (cTFA)

Measurement of the acute intersection angle of the anatomical frontal longitudinal axes of the thigh (spina iliaca anterior superior to the middle of the patella) and lower leg (middle of the patella to the middle of the ankle joint) in neutral joint position.

Unit: ° (Grad)

Tool: Goniometer / Protractor

https://crescnet.org/ (University of Leipzig). This network has been developed by the Medical Faculty of the University of Leipzig and is dependent on financial donations and support in order to be able to fulfill its associated tasks.









Network Endocrine Conditions (Endo-ERN)

Standardized documentation during patient visits - auxology documentation











Network
 Endocrine Conditions
 (Endo-ERN)

Patient demographics

		N=
All registered in CrescNet		258 (131 f)
Foramen magnum surgery		19
Limb lengthening		12
Vosoritide treatment		87
Start of treatment	H-SDS (German reference)	-4.9
	H-SDS (Merker et al.)	0.42
	BMI-SDS	1.68
	Chron. age	9.89 y.
	Bone age	8.79 y.
Treatment duration		0.75 y.








Network
 Endocrine Conditions
 (Endo-ERN)

AFMS-Score (N=93)









Network
 Endocrine Conditions
 (Endo-ERN)












(Endo-ERN)

Bone age (Greulich/ Pyle)



N=110	
>1 years retarded	54 (49.1%)
+/- 1y.	51 (46.4%)
≥ 1 y. accelerated	5 (4.55%)


Chron. age (years)







Bone age in bone dysplasia determined by prior-free deep learning (pilot project S. Rassmann, Univ. Bonn)










Bone age in bone dysplasia determined by prior-free deep learning (pilot project S. Rassmann, Univ. Bonn) Blant-Altmann-Plot











Graphical Visualization - CrescNet®

Disease-related references

Merker A et al.: Growth in achondroplasia: Development of height, weight, head circumference, and body mass index in a European cohort. Am J Med Genet Part A. 2018; 176A: 1723-1734.













Network Endocrine Conditions (Endo-ERN)

Results | Height and weight






Data from Otto-von-Guericke University (OvGU) Magdeburg, Germany







Results | Height SDS vs Treatment










Results | ΔHeight SDS per year vs before and during 1 year treatment



No treatment During treatment







Conclusions in RWE

- ✓ Prospective standardized monitoring by real-time data collection enables evaluation of standard of care (SoC)
- ✓ QR-code to patients for documentation of milestones, mobility and pain score (STEMS), QoL-questionnaires
- Severity of co-morbidities :AFMS-Score of cervico-medullary compression, bone deformities (intercondylar distance, intermaleolar distance, tibiofemoral angle)
- ✓ Bone age:
 - Retardation >> acceleration
 - Low accuracy of Greulich/ Pyle method in bone dysplasia
- \checkmark Response to vosoritide: 1st year Δ H-SDS equals 0.5 SDS